Results 21 to 30 of about 4,608 (197)

Diagnostic Nerve Block to Guide Botulinum Neurotoxin Type A Injection for Clonus in Spastic Equinovarus Foot: A Retrospective Study [PDF]

Toxins
Clonus is characterized by involuntary, rhythmic, oscillatory muscle contractions, typically triggered by rapid muscle stretching and is frequently associated with spastic equinovarus foot (SEVF), where it may increase risk of falls and cause discomfort, pain, and sleep disorders. We hypothesize that selective diagnostic nerve block (DNB) of the tibial
Mirko Filippetti, Stefano Tamburin, Ilaria Di Maria, Cecilia Angeli, Rita Di Censo, Elisa Mantovani, Nicola Smania, Alessandro Picelli   +7 more
openaire   +5 more sources

Does the Diffusion Profile Differ Between Botulinum Toxin Type a Formulations? Implications for the Management of Post-Stroke Spasticity [PDF]

Toxins
Botulinum toxin type A is a first-line treatment for post-stroke spasticity, with selective action at nerve endings and minimal effects beyond the injection site.
Alessandro Picelli, Stefano Tamburin, Rita Di Censo, Nicola Smania, Mirko Filippetti   +4 more
doaj   +2 more sources

Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis [PDF]

Toxicon: X
Within the field of rehabilitation and aesthetic medicine, botulinum neurotoxin (BoNT), particularly type A (BoNT-A), has gained significant popularity for its unique muscle-relaxing properties including muscular spasticity and reducing wrinkles ...
Qiaozhen Li, Chunqiu Dai, Hongbin Wang, Feng Feng, Xiao Xi, Hong Wang, Hua Yuan, Xiaolong Sun   +7 more
doaj   +2 more sources

Cryo‐EM Structure Guided Engineering of Botulinum Neurotoxin A With Advanced Receptor Binding Affinity and Therapeutical Benefits [PDF]

Advanced Science, Volume 13, Issue 33, 15 June 2026.
The butterfly unfolded wing in an open form structure of botulinum neurotoxin type A (BoNT/A) at physiological‐state was confirmed at 2.85 Å resolution by cryo‐electron microscopy (cryo‐EM). Structure‐guided protein engineering significantly enhanced the receptor‐binding affinity, therapeutic efficacy, and safety of the engineered toxin variants ...
Wenrui Wang, Zhaxi Zerang, Linjin You, Ziye Liu, Rong Nie, Fuwei Qi, Fenfen Gao, Chengmu Zhao, Wantong Ma, Jinghan He, Xiaoru Wang, Shanquan Wu, Bo Liu, Xinyao Liu, Dongsheng Lei, Dejuan Zhi, Dongsheng Wang   +16 more
wiley   +2 more sources

Comparative Analytics and Pharmacodynamics of the Complex Protein-Free Botulinum Toxin Type A Formulations DaxibotulinumtoxinA, IncobotulinumtoxinA and RelabotulinumtoxinA [PDF]

Toxins
Botulinum neurotoxin type A (BoNT/A) is intramuscularly injected for the treatment of, e.g., spasticity, cervical dystonia or facial lines. Several BoNT/A products with or without complexing proteins, with non-interchangeable dose units and various ...
Stefanie Honndorf, Katja Kühbach, Karl-Heinz Eisele, Alina Shokurova, Philipp Buch, Claudia Jatzke, Harold Victor Taylor, Klaus Fink   +7 more
doaj   +2 more sources

Intraprostatic Botulinum Neurotoxin Type A Injection for Benign Prostatic Hyperplasia:Preliminary Results with a Newly Purified Neurotoxin

Intraprostatic Botulinum Neurotoxin Type A Injection for Benign Prostatic Hyperplasia:Preliminary Results with a Newly Purified Neurotoxin
Several studies have demonstrated the efficacy of intraprostatic injection of botulinum neurotoxin type A (BoNT/A) against symptomatic benign prostatic hyperplasia (BPH). The most commonly used BoNT/A product, Botox®, forms large complexes and composed of neurotoxin (NTX) as well as non-toxic components. We purified NTX lacking non-toxic components. We
Oguma, Keiji, Suzuki, Tomonori, Yamamoto, Yumiko, Nagai, Atsushi, Yokoyama, Teruhiko   +4 more
openaire   +1 more source

Saliva changes in Parkinson’s disease patients after injection of Botulinum neurotoxin type A [PDF]

Neurological Sciences, 2018
Patients with Parkinson's disease (PD) are compromised by poor oral condition due to oropharyngeal bradykinesia, dysphagia, and the side effects of treatment. Intrasalivary gland injections of Botulinum neurotoxin type A (BNT-A) have been known to treat sialorrhea effectively in these patients.
Janne Tiigimäe-Saar, Tiia Tamme, Marika Rosenthal, Liis Kadastik-Eerme, Pille Taba   +4 more
openaire   +2 more sources

Hemimasticatory spasm. Own experience of using botulinum neuroprotein type A

Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, 2022
Нemimasticatory spasm (HMS) is a rare disorder of the nervous system, in which there are unilateral, violent spasms of the masticatory muscles innervated by the motor portion of the trigeminal nerve.
A. N. Korenko, A. V. Amelin, A. A. Timofeeva   +2 more
doaj   +1 more source

Botulinum Neurotoxin for the Treatment of Neuropathic Pain

Frontiers in Neurology, 2020
Botulinum neurotoxin is widely used for the treatment of central and peripherical neurological conditions. Initially used to treat strabismus, over the years its use has been expanded also to spasticity and other neurological disorders.
Gabriella Egeo, Luisa Fofi, Piero Barbanti, Piero Barbanti   +3 more
doaj   +1 more source

Clostridium botulinum Type B Isolated From a Wound Botulism Case Due to Injection Drug Use Resembles Other Local Strains Originating From Hawaii

Frontiers in Microbiology, 2021
Clostridium botulinum produces botulinum neurotoxin (BoNT), which can lead to death if untreated. In the United States, over 90% of wound botulism cases are associated with injection drug use of black tar heroin.
Jessica L. Halpin, Victoria Foltz, Janet K. Dykes, Kevin Chatham-Stephens, Carolina Lúquez   +4 more
doaj   +1 more source